1. Home
  2. HCWB vs GLMD Comparison

HCWB vs GLMD Comparison

Compare HCWB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$2.91

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$3.94

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
GLMD
Founded
2018
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.2M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
HCWB
GLMD
Price
$2.91
$3.94
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$35.00
N/A
AVG Volume (30 Days)
117.7K
62.8K
Earning Date
05-15-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,099,750.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.41
52 Week High
$6.11
$5.45

Technical Indicators

Market Signals
Indicator
HCWB
GLMD
Relative Strength Index (RSI) 47.53 72.35
Support Level $2.35 $0.54
Resistance Level $4.12 $5.45
Average True Range (ATR) 0.44 0.36
MACD 0.07 0.04
Stochastic Oscillator 44.63 70.81

Price Performance

Historical Comparison
HCWB
GLMD

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.

Share on Social Networks: